Article
Oncology
Gilbert Youssef, Rifaquat Rahman, Camden Bay, Wei Wang, Mary Jane Lim-Fat, Omar Arnaout, Wenya Linda Bi, Daniel N. Cagney, Yuh-Shin Chang, Timothy F. Cloughesy, Matthew DeSalvo, Benjamin M. Ellingson, Thomas F. Flood, Elizabeth R. Gerstner, L. Nicolas Gonzalez Castro, Jeffrey P. Guenette, Albert E. Kim, Eudocia Q. Lee, Jose R. McFaline-Figueroa, Christopher A. Potter, David A. Reardon, Raymond Y. Huang, Patrick Y. Wen
Summary: This study compared the performance of RANO criteria with modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria in patients with newly diagnosed glioblastoma and recurrent GBM. The results showed similar correlations between PFS and OS for RANO and mRANO. Confirmation scans within 12 weeks after radiotherapy improved correlations in nGBM. Using postradiation MRI as the baseline scan had better correlation in nGBM compared to using pre-radiation MRI. Evaluation of FLAIR sequences did not improve the correlation. iRANO criteria did not provide significant benefit in patients receiving immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lei She, Lin Su, Chao Liu
Summary: The purpose of this study was to evaluate the safety, tolerability, and efficacy of a combination of BEV and re-RT for the treatment of rGBM. The results showed that this combination therapy was safe, tolerable, and effective in rGBM patients. Additionally, gross total resection prior to re-RT and selective concurrent temozolomide further improved patient PFS and OS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Cristina Smolenschi, Elie Rassy, Johan Pallud, Edouard Dezamis, Razvan Copaciu, Fabrice Parker, Gabriel Garcia, Naima Lezghed, Emeline Colomba, Mohamed Khettab, Sami Ammari, Mohamed Fekhi, Larisa Martanovschi, Lina Benadhou, Steven Knafo, David Guyon, Bianca Cheaib, Frederic Dhermain, Sarah Naomie Dumont
Summary: This study aimed to assess the real-life benefit of bevacizumab in recurrent glioblastoma patients. The results showed significant improvements in overall survival, time to treatment failure, radiological response, and clinical benefit. Therefore, bevacizumab as a therapeutic option has clinical significance for these patients.
JOURNAL OF NEUROLOGY
(2023)
Article
Immunology
Peng Lin, Hao Jiang, Yu-jia Zhao, Jin-shu Pang, Wei Liao, Yun He, Zhang-Ya Lin, Hong Yang
Summary: The study revealed that rGBM patients have enrichment of activated CD8 T cells, and high CD8 T-cell infiltration is associated with better overall survival. CD8 T cells serve as an independent prognostic factor and could potentially assist in treatment selection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Benjamin M. Ellingson, John Sampson, Achal Singh Achrol, Manish K. Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, John R. Floyd, Seunggu Han, Santosh Kesari, Dina Randazzo, Michael A. Vogelbaum, Frank Vrionis, Miroslaw Zabek, Nicholas Butowski, Melissa Coello, Nina Merchant, Fahar Merchant
Summary: The study compared different neuro-oncology criteria in an immunotherapy trial for recurrent glioblastoma and found a strong correlation between PFS and OS using mRANO, while iRANO required confirmation of progression 3 months later, resulting in more than half of the patients being censored.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Giuseppe Lombardi, Alessandro Spimpolo, Sara Berti, Cristina Campi, Maria giulia Anglani, Rossella Simeone, Laura Evangelista, Francesco Causin, Giovanni Zorzi, Giancarlo Gorgoni, Mario Caccese, Marta Padovan, Vittorina Zagonel, Diego Cecchin
Summary: The aim of this study was to evaluate the ability of [F-18]FET and ADC metrics to identify treatment response and predict overall survival in recurrent glioblastoma patients treated with regorafenib. The results showed that these two metrics performed at least as well as RANO criteria in predicting overall survival, and in some cases even better.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Review
Oncology
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao
Summary: This study aims to provide an evidence map associated with bevacizumab (BEV) therapy for recurrent glioblastoma (rGBM), and the results show that although BEV treatment can improve patients' progression-free survival (PFS) and quality of life, there is insufficient evidence to support its efficacy in prolonging overall survival (OS). BEV combined therapy is more effective than monotherapy, and it is more effective in patients with specific molecular alterations and clinical features. High-quality studies are needed to explore the optimal treatment strategies.
Article
Oncology
Gang Yang, Yu Fang, Ming Zhou, Wei Li, Dapeng Dong, Jing Chen, Yong Da, Kunpeng Wang, Xinru Li, Xiaoyan Zhang, Tonghui Ma, Ge Shen
Summary: We report a case of recurrent glioblastoma with lung metastasis, treated with a combination therapy of bevacizumab and pembrolizumab, which resulted in a longer overall survival. Additionally, this is the first use of bevacizumab plus pembrolizumab as a maintenance treatment for glioblastoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Alvaro Lopez-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Summary: Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, were evaluated in a multicenter phase 1/2 study for the treatment of recurrent glioblastoma. The combination of intratumoral DNX-2401 followed by intravenous pembrolizumab showed notable survival benefit with an objective response rate of 10.4% and overall survival at 12 months of 52.7%. Exploratory analyses suggested potential predictors of treatment response and resistance. Overall, this combination therapy demonstrated promising results in select patients with glioblastoma.
Article
Oncology
Kosuke Takigawa, Nobuhiro Hata, Yuhei Michiwaki, Akio Hiwatashi, Hajime Yonezawa, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Yusuke Funakoshi, Ryosuke Otsuji, Aki Sako, Osamu Togao, Takashi Yoshiura, Koji Yoshimoto, Masahiro Mizoguchi
Summary: Early radiographic response in volumetric GdT1WI improvement is a significant predictive factor for prolonging overall survival in patients with unresectable nd-GBM treated with bevacizumab. The interpretation threshold for improvement in GdT1WI by neuroradiologists is around 20% of volume reduction, which is lower than the 50% definition of partial response in the RANO criteria. Less stringent neuroradiologist interpretation can still successfully predict overall survival prolongation.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Laiz Laura de Godoy, Sanjeev Chawla, Steven Brem, Suyash Mohan
Summary: The highly aggressive nature of glioblastoma poses a challenge in accurately evaluating treatment response. The RANO Working Group proposed revised criteria to differentiate pseudo-progression from true progression based on postcontrast T1-weighted MRI sequences. To address the limitations, our group suggests integrating advanced multimodal neuroimaging techniques and artificial intelligence tools to improve the assessment of early treatment response in neuro-oncology.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
T. Zhang, Q. Xin, J-M Kang
Summary: The study provides evidence of the beneficial effects of bevacizumab treatment in recurrent GBM patients, showing improved ORR and median PFS but no effect on median OS. Adverse events mainly included hypertension in patients receiving bevacizumab treatment compared to standard treatments.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Qingsheng Xu, Kaiyuan Huang, Xiangqi Meng, Yuxiang Weng, Luyuan Zhang, Linghao Bu, Xiujue Zheng, Jinquan Cai, Renya Zhan, Qun Chen
Summary: The combination of anlotinib and temozolomide showed high efficacy and tolerability in treating recurrent GBM, with a good tumor response rate and disease control rate. This treatment regimen may contribute to an increase in progression-free survival and overall survival in patients with recurrent GBM.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Summary: The study investigated the safety and efficacy of Evo in combination with bevacizumab for treating bevacizumab refractory glioblastoma patients. Results showed a median overall survival of approximately 4.6 months with a median time to disease progression of 53 days from best response. The progression free survival at 4 months (PFS-4) on Evo-Bev treatment demonstrated a statistically significant improvement.
SCIENTIFIC REPORTS
(2021)
Review
Clinical Neurology
J. Jacob, L. Feuvret, J-M Simon, M. Ribeiro, L. Nichelli, C. Jenny, D. Ricard, D. Psimaras, K. Hoang-Xuan, P. Maingon
Summary: Radiation therapy is a major treatment for cancer patients, and advances in technology have improved its accuracy and reduced damage to healthy tissue. This literature review provides a comprehensive description of the physiological processes, neurological symptoms, and imaging changes seen after radiation therapy. It also discusses specific treatment options and preventive measures.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Marc Bertaux, Arnaud Berenbaum, Anna-Luisa Di Stefano, Laura Rozenblum, Marine Soret, Sebastien Bergeret, Khe Hoang-Xuan, Laure-Eugenie Tainturier, Brian Sgard, Marie-Odile Habert, Jean-Yves Delattre, Caroline Dehais, Ahmed Idbaih, Nadya Pyatigorskaya, Aurelie Kas
Summary: Our scoring approach combining F-DOPA PET and MRI provides better accuracy than conventional PET analyses for distinguishing TP from TRC in patients with glioma after radiotherapy.
CLINICAL NEURORADIOLOGY
(2022)
Article
Psychology, Clinical
M. Espinola-Nadurille, M. Restrepo-Martinez, L. Bayliss, E. Flores-Montes, V Rivas-Alonso, S. Vargas-Canas, L. Hernandez, I Martinez-Juarez, A. Gonzalez-Aguilar, R. Solis-Vivanco, G. L. Fricchione, J. Flores-Rivera, J. Ramirez-Bermudez
Summary: This study aimed to determine the behavioral hallmarks of anti-NMDA receptor encephalitis (ANMDARE). After systematic neuropsychiatric and cognitive assessments on 160 patients, the typical neuropsychiatric patterns of ANMDARE were found to be psychosis, delirium, catatonia, anxiety-depression, and mania. Cognitive function was also significantly impaired, with 34% of patients presenting predominantly neuropsychiatric symptoms without seizures.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Oncology
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.
Letter
Oncology
Alice Laurenge, Renata Ursu, Emeline Tabouret, Vincent Harlay, Guido Ahle, Sylvain Choquet, Carole Soussain, Cecile Molucon-Chabrot, Bertrand Mathon, Karima Mokhtari, Valerie Pourcher, Lucia Nichelli, Stephane Marot, Mehdi Touat, Khe Hoang-Xuan, Caroline Houillier
LEUKEMIA & LYMPHOMA
(2023)
Review
Clinical Neurology
L. Nguyen-Them, A. Alentorn, G. Ahle, C. Soussain, B. Mathon, M. Le Garff Tavernier, C. Houillier, K. Hoang-Xuan
Summary: PCNSL is a highly aggressive non-Hodgkin lymphoma that affects the brain, spinal cord, eyes, and leptomeninges. Early diagnosis is crucial for effective management, but it can be challenging due to misleading radiological presentations, steroid response bias, and contraindications for brain biopsy. In this review, various CSF biomarkers for diagnosis and prognosis of PCNSL will be discussed, highlighting their advantages and limitations.
REVUE NEUROLOGIQUE
(2023)
Review
Oncology
Laura Rozenblum, Caroline Houillier, Carole Soussain, Marc Bertaux, Sylvain Choquet, Damien Galanaud, Khe Hoang-Xuan, Aurelie Kas
Summary: Primary central nervous system lymphoma (PCNSL) is a rare but highly aggressive lymphoma with increasing incidence in immunocompetent patients. Age and functional status are the only established biomarkers for survival. The magnetic resonance imaging (MRI) criteria of the International Collaborative Group on Primary Central Nervous System Lymphoma are recommended for follow-up. F-18-fluorodeoxyglucose body positron emission tomography has been established for identification of systemic disease, but the role of brain PET scan is less clear.
Article
Oncology
I. Hernandez-Verdin, E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, H. Loiseau, A. Rousseau, J. Paillassa, G. Ahle, F. Lerintiu, E. Uro-Coste, L. Oberic, D. Figarella-Branger, O. Chinot, G. Gauchotte, L. Taillandier, J. -P. Marolleau, M. Polivka, C. Adam, R. Ursu, A. Schmitt, N. Barillot, L. Nichelli, F. Lozano-Sanchez, M. -J. Ibanez-Julia, M. Peyre, B. Mathon, Y. Abada, F. Charlotte, F. Davi, C. Stewart, A. de Reynies, S. Choquet, C. Soussain, C. Houillier, B. Chapuy, K. Hoang-Xuan, A. Alenorn
Summary: Through comprehensive multi-omic analysis, we identified and characterized four molecular patterns in PCNSL, which have a distinct prognostic impact and can guide future clinical stratification and targeted interventions.
ANNALS OF ONCOLOGY
(2023)
Article
Clinical Neurology
Jaime Gallego Perez-Larraya, Marc Garcia-Moure, Marta M. Alonso
Summary: Diffuse intrinsic pontine glioma (DIPG) is the deadliest brain tumor in children and current treatments offer little benefit. A study conducted a phase 1 clinical trial using an oncolytic adenovirus, Delta-24-RGD, injected directly into the tumor. The treatment showed a good safety profile and promising efficacy results, highlighting the potential of oncolytic viruses for treating devastating tumors like DIPG.
REVUE NEUROLOGIQUE
(2023)
Article
Clinical Neurology
Michele Breda-Yepes, Luis A. Rodriguez-Hernandez, Enrique Gomez-Figueroa, Michel G. Mondragon-Soto, Gerardo Arellano-Flores, Alan Hernandez-Hernandez, Hector A. Rodriguez-Rubio, Pablo Martinez, Ignacio Reyes-Moreno, Juan A. Alvaro-Heredia, Guillermo A. Gutierrez Aceves, Eliezer Villanueva-Castro, Marcos Sangrador-Deitos, Mario Alonso-Vanegas, Vicente Guerrero-Juarez, Alberto Gonzalez-Aguilar
Summary: This study aimed to assess whether relative cerebral blood volume (rCBV) from dynamic susceptibility-weighted contrast-enhanced MRI (DSC-MRI) could predict response in patients with glioblastoma undergoing Bevacizumab (BVZ) treatment. The results showed a significant difference in rCBV between patients who responded and those who did not respond to BVZ treatment, suggesting that rCBV may be a low-cost and effective marker to assess response to Bevacizumab treatment in GBM.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2023)
Article
Medicine, General & Internal
Juan Antonio Alvaro-Heredia IV, Noe Alejandro Salazar Felix, German Lopez-Valencia, Tomas Moncada-Habib, Jorge Ivan Castro-Vega, Luis A. Rodriguez-Hernandez, Michel Mondragon-Soto, Marco Antonio Munuzuri-Camacho, Isidro Alvaro-Heredia, Alberto Gonzalez-Aguilar
Summary: This study investigated the epidemiology of meningiomas in Mexico, finding that 69.4% of patients were women and the most common lesion location was convexity meningiomas. The most frequent histopathological types were transitional, meningothelial, and fibroblastic meningiomas.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)